Biogen, Envisagenics collaborate on RNA splicing

By The Science Advisory Board staff writers

Biogen and Envisagenics have announced a new collaboration to advance RNA splicing research within central nervous system (CNS) diseases.

As part of the collaboration, Biogen will leverage Envisagenics' proprietary artificial intelligence-driven RNA splicing platform, SpliceCore, to define and understand the regulation of different RNA isoforms in CNS cell types.

The collaboration aims to identify, test, and validate splicing errors at scale. Biogen will gain access to SpliceCore's database of approximately 7 million potential RNA splicing errors, providing Biogen with a broader lens to evaluate splicing events that may be targeted for therapeutic gain.

Financial details of the collaboration were not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?